Figure 6 | Scientific Reports

Figure 6

From: Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib

Figure 6

Pyrazinib (P3) significantly reduces secretion of IL-1β and increases secretion of IL-3 and IL-17B from OAC treatment biopsies. The effect of 24 h treatment of OAC treatment-naïve biopsies with 0.1% DMSO or 10 µM Pyrazinib (P3) on protein secretion was assessed by multiplex ELISA. (A) Pyrazinib (P3) significantly reduced the secretion of IL-1β from OAC treatment-naïve biopsies, (n = 22). (B) Pyrazinib (P3) significantly increases the secretion of IL-3 from OAC pre-treatment biopsies, (n = 15). (C) Pyrazinib (P3) significantly increases the secretion of IL-17B from OAC pre-treatment biopsies, (n = 15). Wilcoxon signed rank t-test,*p < 0.05, **p < 0.01. All data normalised to protein content. Data expressed as + SEM.

Back to article page